Physician profile
Maureen E Thyne
NPI 1316194020
$109,487.25
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $25K · 2023: $27K · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $19K · Consulting Fee: $4,147 · Food and Beverage: $3,480 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,848.00 |
| Travel and Lodging | $19,062.95 |
| Consulting Fee | $4,146.50 |
| Food and Beverage | $3,480.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $87,120.88 | 2021-2025 | Jakafi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $8,627.42 | 2021-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $5,336.39 | 2023-2025 | Ojjaara |
| Celgene Corporation | $3,719.61 | 2021-2025 | Reblozyl |
| Abbvie INC. | $3,454.14 | 2022-2024 | |
| Cti Biopharma Corp. | $467.03 | 2022-2023 | Vonjo |
| Takeda Pharmaceuticals U.S.A., INC. | $197.72 | 2021-2024 | Iclusig |
| Rigel Pharmaceuticals, INC. | $136.56 | 2022-2023 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $113.08 | 2023-2025 | Vanflyta |
| Servier Pharmaceuticals LLC | $77.39 | 2023-2024 | |
| Sobi, INC | $70.78 | 2024 | |
| Pfizer INC. | $33.18 | 2024 | |
| Blueprint Medicines Corporation | $26.04 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $25.08 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.90 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $22.08 | 2023 | |
| Pharmaessentia USA Corporation | $20.58 | 2023 | Besremi |
| Novartis Pharmaceuticals Corporation | $16.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Thyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.